110 related articles for article (PubMed ID: 37415407)
1. A
Smith SC; Yu J; Paul AK
Int J Surg Pathol; 2024 May; 32(3):539-542. PubMed ID: 37415407
[TBL] [Abstract][Full Text] [Related]
2. TFEB Rearranged Renal Cell Carcinoma: Pathological and Molecular Characterization of 10 Cases, with Novel Clinical Implications: A Single Center 10-Year Experience.
Wang AX; Tian T; Liu LB; Yang F; He HY; Zhou LQ
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830782
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive study of nine novel cases of TFEB-amplified renal cell carcinoma: an aggressive tumour with frequent PDL1 expression.
Kammerer-Jacquet SF; Gandon C; Dugay F; Laguerre B; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Leroy X; Aubert S; Vermaut C; Escande F; Verkarre V; Compérat E; Ambrosetti D; Pedeutour F; Belaud-Rotureau MA; Rioux-Leclercq N;
Histopathology; 2022 Aug; 81(2):228-238. PubMed ID: 35562857
[TBL] [Abstract][Full Text] [Related]
4. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.
Skala SL; Xiao H; Udager AM; Dhanasekaran SM; Shukla S; Zhang Y; Landau C; Shao L; Roulston D; Wang L; Siddiqui J; Cao X; Magi-Galluzzi C; Zhang M; Osunkoya AO; Smith SC; McKenney JK; Betz BL; Myers JL; Chinnaiyan AM; Tomlins SA; Mehra R
Mod Pathol; 2018 Jan; 31(1):179-197. PubMed ID: 28840857
[TBL] [Abstract][Full Text] [Related]
5. Incidental Detection of
Repetto F; Sirohi D; Greipp P; Mahlow J
Int J Surg Pathol; 2024 May; 32(3):551-555. PubMed ID: 37394760
[No Abstract] [Full Text] [Related]
6. Prognosis and Clinicopathological Characters of Adult TFEB-Altered Renal Cell Carcinoma: A Single Center Experience of 18 Cases.
Wu J; Cao CZ; Cui HL; Du G; Shi HZ; Liang J; Guo L; Wang YC; Zhang J; Zhou AP; Li CL; Zheng S; Shou JZ
Clin Genitourin Cancer; 2024 Apr; 22(2):261-268.e3. PubMed ID: 38104031
[TBL] [Abstract][Full Text] [Related]
7. Histological and molecular characterization of TFEB-rearranged renal cell carcinomas.
Wyvekens N; Rechsteiner M; Fritz C; Wagner U; Tchinda J; Wenzel C; Kuithan F; Horn LC; Moch H
Virchows Arch; 2019 May; 474(5):625-631. PubMed ID: 30706129
[TBL] [Abstract][Full Text] [Related]
8. Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma.
Walter B; Gil S; Naizhen X; Kruhlak MJ; Linehan WM; Srinivasan R; Merino MJ
J Cancer; 2020; 11(12):3596-3603. PubMed ID: 32284756
[TBL] [Abstract][Full Text] [Related]
9. TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1.
Zhang C; Duan Y; Xia M; Dong Y; Chen Y; Zheng L; Chai S; Zhang Q; Wei Z; Liu N; Wang J; Sun C; Tang Z; Cheng X; Wu J; Wang G; Zheng F; Laurence A; Li B; Yang XP
Clin Cancer Res; 2019 Nov; 25(22):6827-6838. PubMed ID: 31383732
[TBL] [Abstract][Full Text] [Related]
10. TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1.
Caliò A; Harada S; Brunelli M; Pedron S; Segala D; Portillo SC; Magi-Galluzzi C; Netto GJ; Mackinnon AC; Martignoni G
Mod Pathol; 2021 Apr; 34(4):842-850. PubMed ID: 33208882
[TBL] [Abstract][Full Text] [Related]
11. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
Trpkov K; Hes O; Williamson SR; Adeniran AJ; Agaimy A; Alaghehbandan R; Amin MB; Argani P; Chen YB; Cheng L; Epstein JI; Cheville JC; Comperat E; da Cunha IW; Gordetsky JB; Gupta S; He H; Hirsch MS; Humphrey PA; Kapur P; Kojima F; Lopez JI; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Menon S; Netto GJ; Przybycin CG; Rao P; Rao Q; Reuter VE; Saleeb RM; Shah RB; Smith SC; Tickoo S; Tretiakova MS; True L; Verkarre V; Wobker SE; Zhou M; Gill AJ
Mod Pathol; 2021 Jul; 34(7):1392-1424. PubMed ID: 33664427
[TBL] [Abstract][Full Text] [Related]
12. Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma.
Chandrasekaran D; Sundaram S; N K; R P
Asian Pac J Cancer Prev; 2019 Oct; 20(10):2951-2957. PubMed ID: 31653140
[TBL] [Abstract][Full Text] [Related]
13. The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges.
Mohanty SK; Lobo A; Cheng L
Hum Pathol; 2023 Jun; 136():123-143. PubMed ID: 36084769
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas.
Harada S; Caliò A; Janowski KM; Morlote D; Rodriguez Pena MD; Canete-Portillo S; Harbi D; DeFrank G; Magi-Galluzzi C; Netto GJ; Martignoni G; Mackinnon AC
Mod Pathol; 2021 Nov; 34(11):2055-2063. PubMed ID: 34148064
[TBL] [Abstract][Full Text] [Related]
15. The new WHO 2022 category of molecularly defined renal carcinomas: Accessible to practicing pathologists.
Smith SC; Wobker SE
Am J Clin Pathol; 2023 Dec; 160(6):545-548. PubMed ID: 37589571
[No Abstract] [Full Text] [Related]
16. Exploration of clinicopathological features of rearranged renal cell carcinoma and TFE3, TFEB, and ALK staining performance in renal entities.
Liu Y; Li X; Fan Y; Xu H; Gu Y; Dong L; Zhou L; Yang X; Wang C
Heliyon; 2023 Apr; 9(4):e15159. PubMed ID: 37089387
[TBL] [Abstract][Full Text] [Related]
17. Microphthalmia family of transcription factors associated renal cell carcinoma.
Xie L; Zhang Y; Wu CL
Asian J Urol; 2019 Oct; 6(4):312-320. PubMed ID: 31768316
[TBL] [Abstract][Full Text] [Related]
18. TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations.
Gupta S; Argani P; Jungbluth AA; Chen YB; Tickoo SK; Fine SW; Gopalan A; Al-Ahmadie HA; Sirintrapun SJ; Sanchez A; Hakimi AA; Mcfarlane T; Salazar PA; Williamson SR; Skala SL; Mehra R; Hes O; Antonescu CR; Ladanyi M; Arcila ME; Reuter VE
Am J Surg Pathol; 2019 Nov; 43(11):1445-1461. PubMed ID: 31600176
[TBL] [Abstract][Full Text] [Related]
19. TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management.
Gupta S; Johnson SH; Vasmatzis G; Porath B; Rustin JG; Rao P; Costello BA; Leibovich BC; Thompson RH; Cheville JC; Sukov WR
Mod Pathol; 2017 Jul; 30(7):998-1012. PubMed ID: 28338654
[TBL] [Abstract][Full Text] [Related]
20. VEGFA amplification/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations.
Caliò A; Brunelli M; Segala D; Pedron S; Doglioni C; Argani P; Martignoni G
Mod Pathol; 2019 Feb; 32(2):258-268. PubMed ID: 30206412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
